Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Dow
Harvard Business School
Express Scripts
Mallinckrodt

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,322,025

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,322,025
Title:Methods and DNA constructs for high yield production of polypeptides
Abstract: The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell.
Inventor(s): Williams; James A. (Lincoln, NE), Luan; Peng (Fishers, IN), Xia; Yuannan (Lincoln, NE), Harley; Scott (Pensacola, FL)
Assignee: Medtronic, Inc. (Minneapolis, MN)
Application Number:12/358,966
Patent Claims:1. An expression cassette comprising a nucleotide sequence with the operably linked nucleic acid sequences: 5' Pr-(TIS).sub.D(IBFP1).sub.E-(CL1).sub.G-ORF-[CL2-ORF].sub.L-(CL3).sub.M-(- IBFP2).sub.Q-(SSC).sub.R-(CL4).sub.T-(Ft).sub.W-(Tr).sub.X-3' wherein the Pr is a promoter sequence, the TIS encodes a translation initiation sequence, the IBFP1 encodes a first inclusion body fusion partner comprising an amino acid sequence of any of SEQ ID NOS: 7-14 or a variant thereof, wherein the variant has 75% or greater sequence homology to at least one of SEQ ID NOS: 7-14 and wherein the variant includes a hydrophobic core consisting of residues 22-29 of SEQ ID NO:130, the CL1 encodes a first cleavable peptide linker, the ORFs encode a preselected polypeptide, the CL2 encodes a second cleavable peptide linker, the CL3 encodes a third cleavable peptide linker, the IBFP2 encodes a second inclusion body fusion partner comprising an amino acid sequence of any of SEQ ID NOS: 7-14 or a variant thereof, wherein the variant has 75% or greater sequence homology to at least one of SEQ ID NOS: 7-14 and wherein the variant includes the hydrophobic core consisting of residues 22-29 of SEQ ID NO:130, the SSC is a suppressible stop codon, the CL4 encodes a fourth cleavable peptide linker, the Ft encodes a fusion tag, and the Tr is a transcription terminator sequence, wherein each of D or X is independently 0 or an integer of 1 to 4, wherein R is 0 or an integer of 1 to 2, wherein each of E, G, L, M, Q, T or W is independently 0 or an integer of 1 to 20, wherein either one or both of a IBFP1 or a IBFP2 is present, and wherein expression of the nucleic acid sequence produces a tandem polypeptide that forms an inclusion body when expressed in a cell, wherein at least one of a CL1, a CL2, a CL3 or a CL4 is present.

2. The expression cassette of claim 1 further comprising a nucleic acid sequence that encodes a signal sequence that is operably linked to the amino-terminus or the carboxyl-terminus of the tandem polypeptide.

3. The expression cassette of claim 2, wherein the signal sequence directs the operably linked tandem polypeptide to a periplasmic space, to an inner membrane, or to an outer membrane of the cell.

4. The expression cassette of claim 2, wherein the signal sequence is obtained from a protein selected from the group consisting of a phage fd major coat protein, a phage fd minor coat protein, an alkaline phosphatase, a maltose binding protein, a leucine-specific binding protein, a .beta.-lactamase, a lipoprotein, a LamB and an OmpA.

5. The expression cassette of claim 1, wherein the nucleic acid sequence of either or both of the IBFP1 or the IBFP2 encodes an inclusion body fusion partner that modulates isolation enhancement of an inclusion body formed from the tandem polypeptide.

6. The expression cassette of claim 5, wherein the isolation enhancement of the inclusion body is self-adhesion, solubility, purification stability, resistance to proteolysis, or altered isoelectric point.

7. The expression cassette of claim 1, wherein the promoter includes an operator selected from the group consisting of a lac operator, a lambda phage operator, a .beta.-galactosidase operator, an arabinose operator, a lexA operator, and a trp operator.

8. The expression cassette of claim 1, wherein the promoter is a T7lac promoter, a tac promoter, a lac promoter, a lambda phage promoter, a heat shock promoter, or a chlorella virus promoter.

9. The expression cassette of claim 1, wherein the translation initiation sequence is obtained from a gene encoding a protein selected from the group consisting of a phage T7 gene 10, a phage Q.beta. A, a phage Q.beta. coat, a phage Q.beta. replicase, a phage lambda Cro, a phage fl coat, a phage .phi.X174 A, a phage .phi.X174 B, a phage .phi.X174 E, a lipoprotein, a RecA, a GalE, a GalT, a Lad, a LacZ, aRibosomal L10, a Ribosomal L7/L12, and a RNA polymerase .beta. subunit.

10. The expression cassette of claim 1, wherein each of the first cleavable peptide linker, the second cleavable peptide linker, the third cleavable peptide linker, or the fourth cleavable peptide linker can independently be cleaved by a cleavage agent selected from the group consisting of a palladium, a cyanogen bromide, a Clostripain, a Thrombin, a Trypsin, a Trypsin-like protease, a Carboxypeptidase, an Enterokinase, a Kex 2 protease, an Omp T protease, a Factor Xa protease, a Subtilisin, a HIV protease, a Rhinovirus protease, a Furilisin protease, an IgA protease, a Human Pace protease, a Collagenase, a Plum pos potyvirus, a Poliovirus 2Apro protease, a Poliovirus 3C protease, a Nia protease, a Genenase, a Furin, a Chymotrypsin, an Elastase, a Subtilisin, a Proteinase K, a Pepsin, a Rennin, a microbial aspartic proteases, a Papain, a Ficin, a Bromelain, a Collagenase, a Thermolysin, an Endoprotease Arg-C, an Endoprotease Glu-C, an Endoprotease Lys-C, a Kallikrein and a Plasmin.

11. The expression cassette of claim 1, wherein the ORF encodes a GLP-1, a GLP-2, a PTH, a GRF, a clostripain, or a variant thereof.

12. The expression cassette of claim 1, wherein the ORF contains a suppressible stop codon.

13. The expression cassette of claim 1, wherein the suppressible stop codon is an amber codon or an ochre codon.

14. The expression cassette of claim 13, wherein the suppressible stop codon creates a cleavable peptide linker.

15. The expression cassette of claim 14, wherein the cleavable peptide linker is cleaved by a tissue specific protease.

16. The expression cassette of claim 15, wherein the tissue specific protease is a prostate specific antigen.

17. The expression cassette of claim 1, wherein the fusion tag is a .beta.-gal, a GST, a CAT, a TrpE, a SPA, a SPG, a MBP, a SBD, a CBD.sub.CenA, a CBD.sub.Cex, a Biotin-binding domain, a recA, Flag, a poly(Arg), a Poly(Asp), a Glutamine, a poly(His), a poly(Phe), a poly(Cys), a green fluorescent protein, a red fluorescent protein, a yellow fluorescent protein, a cayenne fluorescent protein, a biotin, an avidin, a streptavidin, or an antibody epitope.

18. The expression cassette of claim 1, wherein the termination sequence is a T7 terminator.

19. A nucleic acid construct comprising a vector operably linked to the expression cassette of claim 1.

20. The nucleic acid construct of claim 19, wherein the vector is a virus, a plasmid, a phagemid, a bacterial artificial chromosome, a yeast artificial chromosome, a bacteriophage, an f-factor, or a cosmid.

21. A cell comprising the nucleic acid construct of claim 19.

22. The cell of claim 21, wherein the cell is a prokaryotic cell or a eukaryotic cell.

23. The cell of claim 21, wherein the cell is a bacterium.

24. The cell of claim 23, wherein the bacterium is Escherichia coli.

25. The cell of claim 21, wherein the cell is a yeast cell, an insect cell or a mammalian cell.

26. The expression cassette of claim 1, wherein at least one of the first cleavable peptide linker, the second cleavable peptide linker, the third cleavable peptide linker, and the fourth cleavable peptide linker is cleavable by palladium.

27. The expression cassette of claim 1, wherein the amino acid at residue 23 of SEQ ID NO:130 is threonine.

28. The expression cassette of claim 1, wherein the amino acid at residue 28 of SEQ ID NO:130 is lysine.

29. The expression cassette of claim 1, wherein the amino acid at residue 23 of SEQ ID NO:130 is threonine and the amino acid at residue 28 of SEQ ID NO:130 is lysine.

30. An expression cassette comprising a nucleotide sequence with the operably linked nucleic acid sequences: 5' Pr-(TIS).sub.D(IBFP1).sub.E-(CL1).sub.G-ORF-[CL2-ORF].sub.L-(CL3).sub.M-(- IBFP2).sub.Q-(SSC).sub.R-(CL4).sub.T-(Ft).sub.W-(Tr).sub.X-3' wherein the Pr is a promoter sequence, the TIS encodes a translation initiation sequence, the IBFP1 encodes a first inclusion body fusion partner comprising an amino acid sequence of any of SEQ ID NOS: 2-6, 12, or 15 or a variant thereof, wherein the variant has 75% or greater sequence homology to at least one of SEQ ID NOS: 2-6, 12, or 15 and wherein the variant includes a hydrophobic core consisting of the amino acid sequence of SEQ ID NO:92 or the amino acid sequence of SEQ ID NO:92 with a single amino acid substitution therein, the CL1 encodes a first cleavable peptide linker, the ORFs encode a preselected polypeptide, the CL2 encodes a second cleavable peptide linker, the CL3 encodes a third cleavable peptide linker, the IBFP2 encodes a second inclusion body fusion partner comprising an amino acid sequence of any of SEQ ID NOS: 2-6, 12, or 15 or a variant thereof, wherein the variant has 75% or greater sequence homology to at least one of SEQ ID NOS: 2-6, 12, or 15 and wherein the variant includes the hydrophobic core consisting of SEQ ID NO:92 or a sequence having a single amino acid substitution of SEQ ID NO:92, the SSC is a suppressible stop codon, the CL4 encodes a fourth cleavable peptide linker, the Ft encodes a fusion tag, and the Tr is a transcription terminator sequence, wherein each of D or X is independently 0 or an integer of 1 to 4, wherein R is 0 or an integer of 1 to 2, wherein each of E, G, L, M, Q, T or W is independently 0 or an integer of 1 to 20, wherein either one or both of a IBFP1 or a IBFP2 is present, and wherein expression of the nucleic acid sequence produces a tandem polypeptide that forms an inclusion body when expressed in a cell, wherein at least one of a CL1, a CL2, a CL3 or a CL4 is present.

31. The expression cassette of claim 30, wherein the amino acid substitution is at residue 4 of SEQ ID NO:92.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Medtronic
Harvard Business School
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.